Fisher & Paykel Healthcare Corporation Limited: Director Shareholding Adjustment and Market Context

Director Shareholding Update

On 3 June 2026, Fisher & Paykel Healthcare Corporation Limited (FPHC) disclosed that its director, Graham Andrew McLean, increased his beneficial shareholding from 3,900 to 4,900 ordinary shares. The transaction, executed on 2 June 2026, was valued at AUD 30 per share.

The purchase was reported through the New Zealand Exchange (NZX) ongoing disclosure notice system, satisfying the obligations under the Financial Markets Conduct Act. Mr. McLean holds the shares via the McLean Superfund, ensuring transparency regarding the source and nature of the holdings.

Market Performance Overview

During the same week, the Net Asset Value (NAV) of the Kingfish Limited portfolio—in which FPHC is a leading constituent—closed at $1.2702 per share on 31 May 2026, a modest increase over the prior close. The portfolio’s performance is directly influenced by FPHC’s share price movements. The slight premium in the NAV calculation reflects the incremental contribution of FPHC’s market performance to the overall portfolio valuation.

Regulatory and Corporate Actions

FPHC was mentioned in several regulatory announcements concerning its share buyback program and other corporate actions. These disclosures highlight the company’s continued engagement with shareholders and its commitment to adherence to disclosure obligations. The buyback activity, coupled with the recent director shareholding adjustment, underscores FPHC’s proactive stance on capital management and shareholder value creation.

Key Takeaways for Stakeholders

  • Director’s increased stake indicates confidence in FPHC’s long‑term prospects.
  • NAV uplift reflects the positive market reception of FPHC’s shares within the Kingfish portfolio.
  • Regulatory compliance demonstrates FPHC’s adherence to market transparency standards, fostering trust among investors and regulators alike.